Pfizer Pflash: A Spotlight on Cancer Cachexia and Ponsegromab

an investigational monoclonal antibody targeting growth differentiation factor-15 (GDF-15)

Pfizer
Research & Development

Forward-Looking Statements and Other Notices

Our discussions during this presentation will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-looking statements about, among other topics, ponsegromab, an investigational monoclonal antibody designed to treat cachexia, including its potential benefits and late-stage development planning, and Pfizer's cardiometabolic portfolio, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data, including results from the Phase 2 study of ponsegromab in patients with heart failure; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any jurisdictions for any potential indication for ponsegromab or any other cardiometabolic product candidates; whether and when any such applications that may be filed for ponsegromab or any other such product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether ponsegromab or any such other product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of ponsegromab or any such other product candidates; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments. Such statements are forward-looking and are estimates that are subject to change and subject to, among other risks, assumptions and uncertainties, clinical trial, regulatory and commercial success, demand, availability of supply, and competitive and market dynamics.

These statements may be affected by underlying assumptions that may prove inaccurate or incomplete, and are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in Pfizer's subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Potential risks and uncertainties also include global economic and/or geopolitical instability, foreign exchange rate fluctuations and inflationary pressures and the impact of COVID-19 on our sales and operations, including impacts on employees, manufacturing, supply chain, marketing, research and development and clinical trials. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.

Today's discussions and presentation are intended for the investor community only; they are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. Definitive conclusions cannot be drawn from cross-trial comparisons or anticipated data as they may be confounded by various factors and should be interpreted with caution.

Pfizer Research & Development

Today's Speakers

Hosted by
Francesca DeMartino
Chief Investor Relations Officer

Charlotte Allerton
Head, Discovery & Early Development



William Sessa
Chief Scientific Officer, Internal Medicine

Aditi Saxena
VP, Clinical Research
Head, Internal Medicine

Pfizer Research & Development

GDF-15 is a Global Stress Regulator that Drives Cachexia[1]

Goal: neutralization of GDF-15 with ponsegromab to inhibit biological pathways driving cachexia



1. Siddiqui JA et al. Cytokine & Growth Factor Reviews, 64, (2022), 71-83

GDF-15 is a Global Stress Regulator that Drives Cachexia[1]

Goal: neutralization of GDF-15 with ponsegromab to inhibit biological pathways driving cachexia



Ponsegromab

Anti-GDF-15 Monoclonal Antibody

Internally Discovered at Pfizer

Subcutaneously Administered

1. Siddiqui JA et al. Cytokine & Growth Factor Reviews, 64, (2022), 71-83 2. As assessed in Phase 2 by the Anorexia and Cachexia Subscale and the 5-Item Anorexia Symptom Scale of the Functional Assessment of Anorexia Cachexia Treatment (FAACT) instrument

Phase 2 Proof-of-Concept Trial

Phase 2 Study with Once Every 4 Weeks Subcutaneous Dosing for 12 Weeks[1]



Endpoints

Change in Body Weight	Symptoms & Physical Activity	Safety & Tolerability
Primary	*Secondary*	*Secondary*

1. Participants receive three doses with primary endpoint assessed at Week 12; 2. Defined as GDF-15 ≥1,500 pg / mL. Ph: Phase; NSCLC: Non-small cell lung cancer

Primary Endpoint Met: Dose-Dependent Weight Gain with Ponsegromab

Ponsegromab was generally considered safe & well tolerated with increases in body weight at all doses tested in Ph 2

Placebo-Adjusted Weight Gain Exceeds 5% in 400 mg Dose Group at 12 Weeks[1]



Weight Gain >5% Suggested by Cancer Cachexia Endpoints Working Group as Being Clinically Meaningful[2]

1. Crawford et al. European Society for Medical Oncology Congress 2024. 2. Brown LR et al. J Cachexia Sarcopenia Muscle 2024; 15: 816-52.
Ph: Phase; LS: Least squares; CI: Confidence interval

Improvements Across PRO & Functional Domains at Top Dose

Improvements across patient-reported symptoms, overall physical activity, and muscle mass vs. placebo

Secondary Endpoints & Additional Analyses: 400 mg Ponsegromab Dose Group[1]

Endpoint	Placebo-Adjusted Change from Baseline at Week 12, Modeled Mean Difference (95% Credible Interval)	Clinical Relevance
FAACT-Anorexia & Cachexia Subscale	**4.50** (1.29 to 7.77)	Moderate **improvement** in **appetite** and **cachexia** symptoms
FAACT-5-item Anorexia Symptom Scale	**2.39** (0.61 to 4.15)	
Non-sedentary Physical Activity (min/day)	**72** (37 to 107)	Placebo-adjusted increase in daily physical activity **may represent clinically meaningful functional improvement**
Lumbar Skeletal Muscle Index (cm^2/m^2)	**2.04** (0.27 to 3.83)	Overall weight gain accompanied by **increase in skeletal muscle mass**

FAACT=Functional Assessment of Anorexia Cachexia Treatment; PRO: Patient-reported outcome

Pfizer Research & Development

1. Groarke et al. N Engl J Med . 2024 Sep 14. doi: 10.1056/NEJMoa2409515 – Table 2 and Table S16.

Ponsegromab in Cancer Cachexia: Summary



1 Potential to Improve Body Composition & Quality of Life[1]



2 May Enhance Cancer Treatment Tolerance

3 Aim to Start Registration-Enabling Study in 2025



4 Broader Potential with Ph 2 Heart Failure Trial Ongoing

Pfizer Research & Development

1. As assessed in Phase 2 by the Anorexia and Cachexia Subscale and the 5-Item Anorexia Symptom Scale of the Functional Assessment of Anorexia Cachexia Treatment (FAACT) instrument.; Ph: Phase

Q&A Session

Francesca DeMartino
Chief Investor Relations Officer

Charlotte Allerton
Head, Discovery & Early Development



William Sessa
Chief Scientific Officer, Internal Medicine

Aditi Saxena
VP, Clinical Research Head, Internal Medicine

Pfizer Research & Development